See more : China Demeter Financial Investments Limited (8120.HK) Income Statement Analysis – Financial Results
Complete financial analysis of OraSure Technologies, Inc. (OSUR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of OraSure Technologies, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Swarmio Media Holdings Inc. (SWMIF) Income Statement Analysis – Financial Results
- International Precious Minerals Group, Inc. (IPMG) Income Statement Analysis – Financial Results
- ABR Holdings Limited (533.SI) Income Statement Analysis – Financial Results
- Trigon Metals Inc. (TM.V) Income Statement Analysis – Financial Results
- Ondas Holdings Inc. (ONDS) Income Statement Analysis – Financial Results
OraSure Technologies, Inc. (OSUR)
About OraSure Technologies, Inc.
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 405.47M | 387.48M | 233.67M | 171.72M | 154.61M | 181.74M | 167.06M | 128.20M | 119.72M | 106.46M | 98.94M | 87.82M | 81.88M | 75.02M | 77.03M | 71.10M | 82.69M | 68.15M | 69.37M | 54.01M | 40.45M | 32.01M | 32.57M | 30.10M | 10.10M | 9.80M | 9.40M | 68.70M | 5.00M | 4.80M | 3.30M | 3.00M | 3.80M | 3.60M | 3.20M |
| Cost of Revenue | 226.05M | 239.84M | 116.07M | 69.85M | 60.02M | 68.13M | 68.11M | 40.17M | 39.43M | 39.84M | 40.35M | 32.25M | 30.16M | 27.66M | 29.90M | 29.98M | 32.40M | 24.76M | 27.97M | 22.14M | 16.06M | 12.89M | 12.33M | 9.00M | 3.10M | 3.00M | 2.80M | 58.60M | 4.90M | 5.60M | 1.70M | 1.20M | 1.90M | 2.00M | 4.20M |
| Gross Profit | 179.42M | 147.64M | 117.60M | 101.87M | 94.58M | 113.61M | 98.96M | 88.03M | 80.29M | 66.62M | 58.59M | 55.57M | 51.72M | 47.36M | 47.13M | 41.13M | 50.28M | 43.40M | 41.39M | 31.87M | 24.39M | 19.12M | 20.24M | 21.10M | 7.00M | 6.80M | 6.60M | 10.10M | 100.00K | -800.00K | 1.60M | 1.80M | 1.90M | 1.60M | -1.00M |
| Gross Profit Ratio | 44.25% | 38.10% | 50.33% | 59.32% | 61.18% | 62.51% | 59.23% | 68.66% | 67.07% | 62.58% | 59.22% | 63.28% | 63.16% | 63.13% | 61.19% | 57.84% | 60.81% | 63.68% | 59.67% | 59.00% | 60.29% | 59.74% | 62.14% | 70.10% | 69.31% | 69.39% | 70.21% | 14.70% | 2.00% | -16.67% | 48.48% | 60.00% | 50.00% | 44.44% | -31.25% |
| Research & Development | 33.73M | 36.24M | 34.17M | 31.03M | 19.63M | 16.25M | 13.37M | 9.75M | 11.65M | 12.06M | 10.93M | 12.45M | 18.41M | 13.19M | 13.37M | 20.26M | 14.14M | 8.65M | 5.27M | 6.06M | 8.00M | 8.27M | 9.39M | 10.40M | 4.00M | 2.90M | 4.20M | 4.50M | 6.80M | 6.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 58.19M | 68.21M | 50.33M | 42.65M | 35.29M | 38.33M | 29.32M | 28.36M | 25.49M | 23.75M | 21.65M | 22.31M | 20.33M | 16.79M | 18.30M | 37.20M | 37.37M | 29.29M | 28.55M | 27.16M | 17.68M | 14.39M | 14.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 36.32M | 49.24M | 44.75M | 34.46M | 31.87M | 30.61M | 28.53M | 29.65M | 35.09M | 41.12M | 46.47M | 37.09M | 22.38M | 20.73M | 21.22M | 20.92B | 20.06B | 15.92B | 16.06B | 15.15B | 10.76B | 8.07B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 92.18M | 117.44M | 95.08M | 77.11M | 67.16M | 68.93M | 57.85M | 58.01M | 60.58M | 64.87M | 68.12M | 59.40M | 42.71M | 37.52M | 39.52M | 37.20M | 37.37M | 29.29M | 28.55M | 27.16M | 17.68M | 14.39M | 14.73M | 13.81M | 5.70M | 5.40M | 6.70M | 9.80M | 11.20M | 7.80M | 13.90M | 8.20M | 6.10M | 4.40M | 1.40M |
| Other Expenses | 0.00 | 6.48M | 872.00K | 1.65M | 2.72M | 3.29M | 794.00K | 58.00K | 774.00K | 531.00K | 200.00K | -242.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.10M | 700.00K | 700.00K | 700.00K | 1.30M | 1.50M | 1.20M | 1.10M | 1.20M | 900.00K | 500.00K | 300.00K |
| Operating Expenses | 146.74M | 153.68M | 129.25M | 108.14M | 86.79M | 85.18M | 71.22M | 67.76M | 72.24M | 76.93M | 79.05M | 71.84M | 61.12M | 50.71M | 52.89M | 57.46M | 51.50M | 37.94M | 33.82M | 33.22M | 25.68M | 22.66M | 24.12M | 26.31M | 10.40M | 9.00M | 11.60M | 15.60M | 19.50M | 15.10M | 15.00M | 9.40M | 7.00M | 4.90M | 1.70M |
| Cost & Expenses | 372.79M | 393.52M | 245.32M | 178.00M | 146.81M | 153.31M | 139.33M | 107.93M | 111.66M | 116.77M | 119.40M | 104.09M | 91.28M | 78.37M | 82.79M | 87.44M | 83.91M | 62.69M | 61.79M | 55.36M | 41.74M | 35.55M | 36.46M | 35.31M | 13.50M | 12.00M | 14.40M | 74.20M | 24.40M | 20.70M | 16.70M | 10.60M | 8.90M | 6.90M | 5.90M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 63.99K | 151.76K | 737.89K | 3.08B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 10.43M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 172.00K | 316.31K | 316.19K | 361.19K | 345.77K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 20.94M | 14.00M | 11.66M | 9.39M | 7.34M | 6.45M | 6.40M | 5.69M | 5.70M | 6.31M | 6.49M | 7.25M | 4.89M | 3.01M | 3.05M | 3.39M | 2.74M | 1.92M | 2.35M | 2.49M | 2.58M | 2.18M | 2.00M | 2.10M | 700.00K | 700.00K | 700.00K | 1.30M | 1.50M | 1.20M | 1.10M | 1.20M | 900.00K | 500.00K | 300.00K |
| EBITDA | 64.35M | 10.29M | 9.00K | 3.44M | 15.53M | 34.88M | 34.14M | 26.01M | 8.06M | -4.00M | -13.91M | -9.09M | -4.50M | -168.49K | -5.02M | -5.02M | 1.52M | 7.39M | 9.92M | 1.13M | 1.29M | -1.36M | -1.89M | -4.42M | -2.70M | -1.50M | -4.30M | -4.20M | -10.10M | -14.70M | -12.30M | -6.40M | -4.20M | -2.80M | -2.40M |
| EBITDA Ratio | 15.87% | 2.81% | -5.62% | -4.29% | 3.05% | 19.62% | 12.95% | 15.81% | 11.49% | -8.92% | -22.51% | -10.27% | -11.10% | -4.28% | -2.57% | -25.02% | 0.23% | 10.98% | 14.22% | 2.19% | 3.34% | -4.25% | -4.73% | 13.02% | -26.73% | -19.39% | -54.26% | -13.97% | -376.00% | -308.33% | -333.33% | -223.33% | -115.79% | -88.89% | -81.25% |
| Operating Income | 54.08M | -4.67M | -11.65M | -6.28M | -3.02M | 28.43M | 40.24M | 20.27M | 8.06M | -4.80M | -12.16M | -16.27M | -9.40M | -3.35M | -8.79M | -16.33M | -1.22M | 5.46M | 7.57M | -1.36M | -1.29M | -3.54M | -4.33M | -12.81M | -3.40M | -2.20M | -5.00M | -5.50M | -19.40M | -15.90M | -13.40M | -7.60M | -5.10M | -3.30M | -2.70M |
| Operating Income Ratio | 13.34% | -1.20% | -4.99% | -3.65% | -1.95% | 15.64% | 24.09% | 15.81% | 6.73% | -4.51% | -12.29% | -18.53% | -11.48% | -4.47% | -11.42% | -22.97% | -1.47% | 8.02% | 10.92% | -2.51% | -3.18% | -11.06% | -13.30% | -42.56% | -33.66% | -22.45% | -53.19% | -8.01% | -388.00% | -331.25% | -406.06% | -253.33% | -134.21% | -91.67% | -84.38% |
| Total Other Income/Expenses | 2.18M | -9.63M | 872.00K | 1.65M | 2.72M | 3.29M | 794.00K | 58.00K | 774.00K | 531.00K | 200.00K | -242.00K | -312.57K | -142.84K | 357.15K | 7.58M | 5.51M | 3.60M | 2.15M | 797.04K | 176.80K | 198.06K | 633.49K | 90.89K | 200.00K | 400.00K | 800.00K | 5.00M | 11.60M | 100.00K | -1.30M | 300.00K | 200.00K | 400.00K | 200.00K |
| Income Before Tax | 56.26M | -16.48M | -9.29M | -3.52M | 21.33M | 31.72M | 41.03M | 20.32M | 8.83M | -4.27M | -11.96M | -16.51M | -9.71M | -3.50M | -8.44M | -8.75M | 4.29M | 9.06M | 9.72M | -559.64K | -1.11M | -3.34M | -3.70M | -12.72M | -3.20M | -1.90M | -22.50M | -300.00K | -18.50M | -15.60M | -14.70M | -7.20M | -4.90M | -2.90M | -2.60M |
| Income Before Tax Ratio | 13.87% | -4.25% | -3.98% | -2.05% | 13.80% | 17.45% | 24.56% | 15.85% | 7.38% | -4.01% | -12.09% | -18.80% | -11.86% | -4.66% | -10.95% | -12.30% | 5.19% | 13.30% | 14.01% | -1.04% | -2.74% | -10.44% | -11.36% | -42.26% | -31.68% | -19.39% | -239.36% | -0.44% | -370.00% | -325.00% | -445.45% | -240.00% | -128.95% | -80.56% | -81.25% |
| Income Tax Expense | 2.60M | 1.46M | 13.71M | 11.40M | 4.68M | 11.32M | 10.08M | 603.00K | 665.00K | 343.00K | -772.00K | -1.40M | -869.00K | 142.84K | -622.28K | 22.53M | 1.82M | 3.79M | -17.73M | -797.04K | 26.59K | -198.06K | 28.79K | 24.36K | 3.20M | 1.90M | 22.50M | 300.00K | 18.50M | 15.60M | 14.70M | 7.20M | 4.90M | 2.90M | 2.60M |
| Net Income | 53.66M | -17.94M | -23.00M | -14.92M | 16.66M | 20.40M | 30.95M | 19.72M | 8.17M | -4.61M | -11.19M | -15.12M | -8.84M | -3.50M | -7.81M | -31.28M | 2.47M | 5.27M | 27.45M | -559.64K | -1.14M | -3.34M | -3.73M | -12.75M | -3.20M | -1.90M | -22.50M | -300.00K | -18.50M | -15.60M | -14.70M | -7.20M | -4.90M | -2.90M | -2.60M |
| Net Income Ratio | 13.23% | -4.63% | -9.84% | -8.69% | 10.77% | 11.22% | 18.52% | 15.38% | 6.82% | -4.33% | -11.31% | -17.21% | -10.80% | -4.66% | -10.14% | -43.99% | 2.99% | 7.73% | 39.57% | -1.04% | -2.81% | -10.44% | -11.44% | -42.34% | -31.68% | -19.39% | -239.36% | -0.44% | -370.00% | -325.00% | -445.45% | -240.00% | -128.95% | -80.56% | -81.25% |
| EPS | 0.73 | -0.25 | -0.32 | -0.22 | 0.27 | 0.33 | 0.52 | 0.35 | 0.14 | -0.08 | -0.20 | -0.29 | -0.19 | -0.08 | -0.17 | -0.67 | 0.05 | 0.11 | 0.61 | -0.01 | -0.03 | -0.09 | -0.10 | -0.36 | -0.23 | -0.14 | -1.12 | -0.02 | -1.04 | -1.07 | -1.11 | -0.55 | -0.43 | -0.29 | -0.31 |
| EPS Diluted | 0.72 | -0.25 | -0.32 | -0.22 | 0.27 | 0.33 | 0.51 | 0.35 | 0.14 | -0.08 | -0.20 | -0.29 | -0.19 | -0.08 | -0.17 | -0.67 | 0.05 | 0.11 | 0.59 | -0.01 | -0.03 | -0.09 | -0.10 | -0.36 | -0.23 | -0.14 | -1.12 | -0.02 | -1.04 | -1.07 | -1.11 | -0.55 | -0.43 | -0.29 | -0.31 |
| Weighted Avg Shares Out | 73.35M | 72.51M | 71.98M | 67.51M | 61.68M | 61.11M | 59.05M | 55.62M | 56.40M | 55.95M | 55.56M | 51.46M | 46.91M | 46.19M | 45.88M | 46.55M | 46.33M | 45.91M | 45.11M | 44.46M | 39.79M | 37.58M | 36.87M | 35.00M | 13.91M | 13.57M | 20.10M | 18.90M | 17.79M | 14.61M | 13.24M | 13.09M | 11.40M | 10.00M | 8.39M |
| Weighted Avg Shares Out (Dil) | 74.39M | 72.51M | 71.98M | 67.51M | 62.17M | 62.53M | 61.02M | 56.51M | 56.85M | 55.95M | 55.56M | 51.46M | 46.91M | 46.19M | 45.88M | 46.55M | 46.88M | 46.58M | 46.15M | 44.46M | 39.79M | 37.58M | 36.87M | 35.00M | 13.91M | 13.57M | 20.10M | 18.90M | 17.79M | 14.61M | 13.24M | 13.09M | 11.40M | 10.00M | 8.39M |
OraSure Technologies, Inc. 2022 First Quarter Earnings Conference Call Tuesday, May 10, 2022, 5:00 p.m. ET
BETHLEHEM, Pa., May 03, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 first quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Tuesday, May...
OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q4 2021 Results - Earnings Call Transcript
OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q4 2021 Results - Earnings Call Transcript
OraSure Technologies, Inc. 2021 Fourth Quarter Earnings Conference Call Wednesday, February 23, 2022, 5:00 p.m. ET
BETHLEHEM, Pa., Feb. 16, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 fourth quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Wednesday, February...
OraSure said its rapid COVID-19 tests can now be used in children
Shares of OraSure Technologies Inc. OSUR, +5.09% gained 2.2% in premarket trading on Monday after the company said its COVID-19 rapid tests have now been authorized for children between the ages of 2 and 14 years old. The tests had...
OraSure's CEO Resigns, Commences Review Of Strategic Alternatives
OraSure Technologies Inc (NASDAQ: OSUR) expects Q4 FY21 revenue at the low end of the Company's guidance range of approximately $60 million. The Company anticipates total InteliSwab revenue of approximately $12 million for Q4 and $20 million for FY21.
OraSure Technologies to Present at Upcoming Investor Conferences
BETHLEHEM, Pa., Nov. 19, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will participate in...
OraSure Technologies' (OSUR) CEO Stephen Tang on Q3 2021 Results - Earnings Call Transcript
OraSure Technologies' (OSUR) CEO Stephen Tang on Q3 2021 Results - Earnings Call Transcript
OraSure Technologies (OSUR) Reports Q3 Loss, Tops Revenue Estimates
OraSure (OSUR) delivered earnings and revenue surprises of -320.00% and 13.41%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
FDA Authorizes OraSure's COVID-19 Rapid Tests For OTC Single-Use
The FDA has amended OraSure Technologies Inc's (NASDAQ: OSUR) Emergency Use Authorization (EUA) for its InteliSwab COVID-19 rapid tests to only require one test for symptoms of COVID-19. Related Link: OraSure Wins $109M Contract To Increase COVID-19 Test Manufacturing Capacity.
OraSure Technologies 2021 Third Quarter Earnings Conference Call Wednesday, November 3, 2021, 5:00 p.m. ET
BETHLEHEM, Pa., Oct. 27, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 third quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Wednesday, November...
Source: https://incomestatements.info
Category: Stock Reports